Historical Valuation
ACADIA Pharmaceuticals Inc (ACAD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.69 is considered Undervalued compared with the five-year average of -6.67. The fair price of ACADIA Pharmaceuticals Inc (ACAD) is between 55.35 to 85.31 according to relative valuation methord. Compared to the current price of 26.78 USD , ACADIA Pharmaceuticals Inc is Undervalued By 51.61%.
Relative Value
Fair Zone
55.35-85.31
Current Price：26.78
51.61%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
ACADIA Pharmaceuticals Inc (ACAD) has a current Price-to-Book (P/B) ratio of 4.85. Compared to its 3-year average P/B ratio of 6.91 , the current P/B ratio is approximately -29.81% higher. Relative to its 5-year average P/B ratio of 6.84, the current P/B ratio is about -29.09% higher. ACADIA Pharmaceuticals Inc (ACAD) has a Forward Free Cash Flow (FCF) yield of approximately 4.45%. Compared to its 3-year average FCF yield of 2.02%, the current FCF yield is approximately 119.74% lower. Relative to its 5-year average FCF yield of -0.47% , the current FCF yield is about -1038.26% lower.
P/B
Median3y
6.91
Median5y
6.84
FCF Yield
Median3y
2.02
Median5y
-0.47
Competitors Valuation Multiple
AI Analysis for ACAD
The average P/S ratio for ACAD competitors is 25.20, providing a benchmark for relative valuation. ACADIA Pharmaceuticals Inc Corp (ACAD.O) exhibits a P/S ratio of 3.69, which is -85.36% above the industry average. Given its robust revenue growth of 11.27%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ACAD
1Y
3Y
5Y
Market capitalization of ACAD increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ACAD in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ACAD currently overvalued or undervalued?
ACADIA Pharmaceuticals Inc (ACAD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.69 is considered Undervalued compared with the five-year average of -6.67. The fair price of ACADIA Pharmaceuticals Inc (ACAD) is between 55.35 to 85.31 according to relative valuation methord. Compared to the current price of 26.78 USD , ACADIA Pharmaceuticals Inc is Undervalued By 51.61% .
What is ACADIA Pharmaceuticals Inc (ACAD) fair value?
ACAD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of ACADIA Pharmaceuticals Inc (ACAD) is between 55.35 to 85.31 according to relative valuation methord.
How does ACAD's valuation metrics compare to the industry average?
The average P/S ratio for ACAD's competitors is 25.20, providing a benchmark for relative valuation. ACADIA Pharmaceuticals Inc Corp (ACAD) exhibits a P/S ratio of 3.69, which is -85.36% above the industry average. Given its robust revenue growth of 11.27%, this premium appears unsustainable.
What is the current P/B ratio for ACADIA Pharmaceuticals Inc (ACAD) as of Jan 10 2026?
As of Jan 10 2026, ACADIA Pharmaceuticals Inc (ACAD) has a P/B ratio of 4.85. This indicates that the market values ACAD at 4.85 times its book value.
What is the current FCF Yield for ACADIA Pharmaceuticals Inc (ACAD) as of Jan 10 2026?
As of Jan 10 2026, ACADIA Pharmaceuticals Inc (ACAD) has a FCF Yield of 4.45%. This means that for every dollar of ACADIA Pharmaceuticals Inc’s market capitalization, the company generates 4.45 cents in free cash flow.
What is the current Forward P/E ratio for ACADIA Pharmaceuticals Inc (ACAD) as of Jan 10 2026?
As of Jan 10 2026, ACADIA Pharmaceuticals Inc (ACAD) has a Forward P/E ratio of 39.74. This means the market is willing to pay $39.74 for every dollar of ACADIA Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for ACADIA Pharmaceuticals Inc (ACAD) as of Jan 10 2026?
As of Jan 10 2026, ACADIA Pharmaceuticals Inc (ACAD) has a Forward P/S ratio of 3.69. This means the market is valuing ACAD at $3.69 for every dollar of expected revenue over the next 12 months.